Verrills Nicole M, Kavallaris Maria
Australian Proteome Analysis Facility, Macquarie University, Sydney, NSW 2109, Australia.
Curr Opin Mol Ther. 2003 Jun;5(3):258-65.
Chemotherapy forms a significant component of the treatment of many human cancers. The failure of tumor cells to respond to the action of cytotoxic drugs is referred to as drug resistance. Mechanisms mediating resistance are multifaceted and often not clearly defined. The challenge of elucidating the link between drug response and resistance, and then integrating the information for the purpose of therapeutic intervention, is a major task that awaits scientists in the post-genomic era. Rapid advances in proteome technologies have made it possible to simultaneously identify multiple proteins involved in drug refractory cancers. This methodology has the potential to isolate novel proteins, including those associated with resistance to specific drugs and those involved in conferring broad resistance to a range of compounds. The identification of key proteins will lead to the possibility of developing molecular, biological or pharmaceutical strategies to modify the action of such proteins when their inappropriate structure or expression is contributing to drug-resistant disease.
化疗是许多人类癌症治疗的重要组成部分。肿瘤细胞对细胞毒性药物作用无反应被称为耐药性。介导耐药性的机制是多方面的，且往往不明确。阐明药物反应与耐药性之间的联系，然后整合这些信息以进行治疗干预，是后基因组时代科学家面临的一项主要任务。蛋白质组技术的快速发展使得同时鉴定参与难治性癌症的多种蛋白质成为可能。这种方法有潜力分离出新的蛋白质，包括那些与对特定药物的耐药性相关的蛋白质以及那些赋予对一系列化合物广泛耐药性的蛋白质。当关键蛋白质的结构或表达不当导致耐药性疾病时，鉴定这些关键蛋白质将有可能开发出分子、生物或药物策略来改变此类蛋白质的作用。
